retatrutide phase 2 study results Effects of on body composition in people with type diabetes: a substudy of a 2, double-blind, parallel-group, placebo-controlled, randomised trial retatrutide phase 2 trial results

One of the most notable investigations, the STEP 1 trial published in The New England Journal of Medicine, reported that participants receiving weekly GLP1-S alongside lifestyle interventions experienced an average 14.9% decrease in body weight across 68 weeks[7][8]

Clinical trial data from the SURMOUNT-1 study showed that up to 29% of participants on tirzepatide for weight loss experienced nausea, primarily during dose escalation phases

You should never stop a medication without talking to your doctor

Injection of unverified, unsterile compounds carries infection and inflammatory risks that are independent of any effects the peptide itself might or might not have